Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Prostate and Urologic Cancer Research Group

Programs and Projects

Prostate Cancer Clinical Trials - University of Texas M.D. Anderson Cancer Center (Mulitcenter sites)

Agent: Finasteride (Proscar)
Contact: Jeri Kim, MD
DCP Program Director: Howard Parnes, MD

The purpose of this study is to learn more about the effects of finasteride on the grade of prostate tumors. Men with a diagnosis of prostate cancer who are considering surgical removal of the prostate gland (prostatectomy) may be eligible to participate in this study. Those taking part in the study will receive finasteride or placebo for several weeks immediately before prostate surgery. The study is being conducted at several clinical centers including the University of Texas M.D. Anderson Cancer Center and will soon be open for enrollment. This study is now open to accrual.

[This is a phase 2, randomized placebo-controlled, double-blind trial of finasteride or placebo administered for 4 - 6 weeks in the presurgical period prior to prostatectomy in men clinical stage T1c or T2; Gleason's grade = 6 (3+3) or 7 (3+4) prostate cancer The primary endpoint is the frequency of discriminating molecular marker expression in Gleason grade (GG) 3 cores of finasteride-treated patients with that in GG 3 cores of placebo-treated patients adjusted for GS at prostatectomy.]